Syndax Pharmaceuticals Income Statement (2015-2026) | SNDX

Income Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.38M12.38M126.58M3.50M12.50M7.68M20.04M37.96M45.87M68.73M64.86M
Cost of Revenue (Quarter)
4.93M0.89M1.28M8.28M9.59M11.85M
Gross Profit (Quarter)
3.50M12.50M2.75M19.16M36.68M37.59M59.13M53.02M
Operating items
Research & Development (Quarter)
16.87M2.00M23.90M30.02M16.00M26.90M31.84M34.05M34.76M39.09M55.13M56.49M48.66M15.00M65.53M61.64M62.23M56.28M78.64M58.84M
Selling, General & Administrative (Quarter)
5.84M6.80M6.93M6.84M7.99M8.24M10.19M11.96M14.91M17.27M22.78M23.02M29.06M31.11M37.69M41.03M43.80M44.92M49.93M37.59M
Restructuring Costs (Quarter)
4.10M11.77M3.85M5.24M4.41M4.99M9.11M4.80M5.14M
Other Operating Expenses (Quarter)
23.61M13.73M-4.10M-11.77M52.12M-4.42M-3.28M-3.71M-7.01M-2.09M-2.51M
Operating Expenses (Quarter)
22.71M32.41M30.83M36.86M37.72M35.14M42.03M46.02M49.68M56.35M77.91M79.51M77.72M102.08M104.05M103.80M107.31M103.30M131.28M99.07M
Operating Income (Quarter)
-22.33M-20.03M95.75M-36.86M-37.72M-35.14M-42.03M-46.02M-49.68M-56.35M-77.91M-79.51M-74.22M-89.58M-96.36M-83.76M-69.35M-57.43M-62.55M-34.20M
EBIT (Quarter)
-22.33M-20.03M95.75M-36.86M-37.72M-35.14M-42.03M-46.02M-49.68M-56.35M-77.91M-79.51M-74.22M-89.58M-96.36M-83.76M-69.35M-57.43M-62.55M-34.20M
Non-operating items
Interest & Investment Income (Quarter)
0.11M0.08M0.09M0.22M0.88M1.78M2.99M5.08M5.19M5.34M5.55M7.26M6.28M5.44M7.11M7.18M5.95M5.27M4.33M3.56M
Other Non Operating Income (Quarter)
-0.05M-0.04M0.35M0.12M-0.03M-0.29M-0.11M-0.15M-0.09M-0.07M-0.06M-0.09M-0.09M0.03M-0.11M-0.22M-0.28M-0.20M-0.19M
Non Operating Income (Quarter)
-0.05M-0.61M1.95M-0.31M0.15M-0.29M2.63M4.89M5.06M5.21M-15.52M7.11M6.15M0.03M-0.11M-1.09M-2.49M-3.29M-11.26M-0.19M
Net income details
EBT (Quarter)
-22.86M-20.60M95.85M-37.28M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.34M-67.98M-84.16M-89.13M-76.58M-63.41M-52.16M-58.22M-30.64M
Profit After Tax (Quarter)
-22.91M-20.64M96.20M-37.17M-37.57M-35.40M-39.19M-41.13M-44.62M-51.15M-72.47M-72.40M-68.06M-84.13M-94.17M-84.85M-71.85M-60.72M-68.01M-42.67M
Income from Continuing Operations (Quarter)
-22.86M-20.60M95.85M-37.28M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.34M-67.98M-84.16M-89.13M-76.58M-63.41M-52.16M-58.22M-30.64M
Consolidated Net Income (Quarter)
-22.86M-20.60M95.85M-37.28M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.34M-67.98M-84.16M-89.13M-76.58M-63.41M-52.16M-58.22M-30.64M
Income towards Parent Company (Quarter)
-22.86M-20.60M95.85M-37.28M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.34M-67.98M-84.16M-89.13M-76.58M-63.41M-52.16M-58.22M-30.64M
Net Income towards Common Stockholders (Quarter)
-22.86M-20.60M95.85M-37.28M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.34M-67.98M-84.16M-89.13M-76.58M-63.41M-52.16M-58.22M-30.64M
Additional items
EPS (Basic) (Quarter)
-0.44-0.401.86-0.63-0.62-0.58-0.62-0.59-0.64-0.73-1.01-0.85-0.80-0.98-1.09-0.98-0.83-0.70-0.78-0.48
EPS (Weighted Average and Diluted) (Quarter)
-0.44-0.401.84-0.63-0.62-0.58-0.62-0.59-0.64-0.73-1.01-0.85-0.80-0.98-1.09-0.98-0.83-0.70-0.78-0.48
Shares Outstanding (Weighted Average) (Quarter)
51.60M51.69M52.06M58.98M59.57M59.94M60.76M69.44M69.54M69.65M70.37M85.21M85.27M85.31M85.62M86.17M86.34M86.62M86.63M88.26M
Shares Outstanding (Diluted Average) (Quarter)
51.55M51.69M58.98M59.57M59.94M69.44M69.64M69.65M85.21M85.27M85.43M86.17M86.26M86.62M88.26M
EBITDA (Quarter)
-22.90M-20.64M95.75M-37.85M-38.27M-35.67M-42.03M-40.66M-44.85M-51.03M-77.91M-73.37M-68.12M-82.94M-96.36M-83.76M-69.35M-57.43M-62.55M-34.20M
Interest Expenses (Quarter)
0.63M0.65M-0.01M0.65M0.69M1.75M0.04M0.04M0.04M0.07M0.06M0.09M0.04M0.02M-0.12M0.00M0.00M